Novartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk

Dow Jones

Oct 01

0646 GMT - Novartis's Rhapsido received approval from the U.S. Food and Drug Administration to treat hives, but the drug is also being evaluated in other conditions that could expand the company's immunology and neuroscience portfolios, Vontobel's Stefan Schneider says. Sales for Rhapsido--commercial name of the drug known until now as remibrutinib--in spontaneous hives, or urticaria, could hit $1.75 billion, according to Vontobel. The Swiss pharmaceutical company is also conducting trials for food allergy and other skin conditions that could expand its immunology portfolio, the analyst says in a research note. The drug is also being studied for multiple sclerosis and myasthenia, which could support growth in Novartis's neuroscience portfolio, he says. Line extensions are likely to make up a large chunk of Novartis's upcoming updates, Vontobel says. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

October 01, 2025 02:47 ET (06:47 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2572586539"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572586539\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572586539?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 14:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572586539","market":"hk","top_or_hot":-1,"title":"Novartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0646 GMT - Novartis's Rhapsido received approval from the U.S. Food and Drug Administration to treat hives, but the drug is also being evaluated in other conditions that could expand the company's immunology and neuroscience portfolios, Vontobel's Stefan Schneider says. Sales for Rhapsido--commercial name of the drug known until now as remibrutinib--in spontaneous hives, or urticaria, could hit $1.75 billion, according to Vontobel. The Swiss pharmaceutical company is also conducting trials for food allergy and other skin conditions that could expand its immunology portfolio, the analyst says in a research note. The drug is also being studied for multiple sclerosis and myasthenia, which could support growth in Novartis's neuroscience portfolio, he says. Line extensions are likely to make up a large chunk of Novartis's upcoming updates, Vontobel says. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 01, 2025 02:47 ET (06:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-01 14:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0646 GMT - Novartis's Rhapsido received approval from the U.S. Food and Drug Administration to treat hives, but the drug is also being evaluated in other conditions that could expand the company's immunology and neuroscience portfolios, Vontobel's Stefan Schneider says. Sales for Rhapsido--commercial name of the drug known until now as remibrutinib--in spontaneous hives, or urticaria, could hit $1.75 billion, according to Vontobel. The Swiss pharmaceutical company is also conducting trials for food allergy and other skin conditions that could expand its immunology portfolio, the analyst says in a research note. The drug is also being studied for multiple sclerosis and myasthenia, which could support growth in Novartis's neuroscience portfolio, he says. Line extensions are likely to make up a large chunk of Novartis's upcoming updates, Vontobel says. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 01, 2025 02:47 ET (06:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2572586539","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572586539","pubTimestamp":1759301220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0646 GMT - Novartis's Rhapsido received approval from the U.S. Food and Drug Administration to treat hives, but the drug is also being evaluated in other conditions that could expand the company's immunology and neuroscience portfolios, Vontobel's Stefan Schneider says. Sales for Rhapsido--commercial name of the drug known until now as remibrutinib--in spontaneous hives, or urticaria, could hit $1.75 billion, according to Vontobel. The Swiss pharmaceutical company is also conducting trials for food allergy and other skin conditions that could expand its immunology portfolio, the analyst says in a research note. The drug is also being studied for multiple sclerosis and myasthenia, which could support growth in Novartis's neuroscience portfolio, he says. Line extensions are likely to make up a large chunk of Novartis's upcoming updates, Vontobel says. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4588":"碎股","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4578":"CAR-T","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4532":"文艺复兴科技持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4007":"制药","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"诺华首次获得FDA批准Rhapsido，后续可能会有更多批准——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"0646 GMT - Novartis's Rhapsido received approval from the U.S. Food and Drug Administration to treat hives, but the drug is also being evaluated in other conditions that could expand the company's immunology and neuroscience portfolios, Vontobel's Stefan Schneider says. Sales for Rhapsido--commercial name of the drug known until now as remibrutinib--in spontaneous hives, or urticaria, could hit $1.75 billion, according to Vontobel. The Swiss pharmaceutical company is also conducting trials for food allergy and other skin conditions that could expand its immunology portfolio, the analyst says in a research note. The drug is also being studied for multiple sclerosis and myasthenia, which could support growth in Novartis's neuroscience portfolio, he says. Line extensions are likely to make up a large chunk of Novartis's upcoming updates, Vontobel says. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 01, 2025 02:47 ET (06:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}